These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38436924)

  • 1. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
    Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
    Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
    Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
    Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
    Falchook G; Patnaik A; Richardson DL; Harvey RD; Sharma MR; Hafez N; Hamilton E; Piha-Paul SA; Barve M; Wise-Draper T; Patel MR; Dowlati A; Pascuzzo J; Tang SC; Faltermeier C; Malinowska IA; Shtessel L; Striha A; Potocka E
    Clin Ther; 2024 Mar; 46(3):228-238. PubMed ID: 38423866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
    Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F
    Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study.
    Wu ZX; Wang CJ; Shi P; Liu YP; Li T; Sun FF; Fu Y; Gao XM; Ma YP; Cao Y
    Drugs R D; 2023 Jun; 23(2):121-127. PubMed ID: 37012461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
    Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
    Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.
    Roubaud G; Attard G; Boegemann M; Olmos D; Trevisan M; Antoni L; Pascoe K; Capone C; Van Sanden S; Hashim M; Palmer S; Chi K
    Eur J Cancer; 2024 Sep; 209():114183. PubMed ID: 39111209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
    Saad F; Chi KN; Shore ND; Graff JN; Posadas EM; Lattouf JB; Espina BM; Zhu E; Yu A; Hazra A; De Meulder M; Mamidi RNVS; Bradic B; Francis P; Hayreh V; Rezazadeh Kalebasty A
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):25-37. PubMed ID: 33754187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
    Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers.
    Wang C; Hu C; Gao D; Zhao Z; Chen X; Hu X; Gong S; Li L; Zhang L
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):509-517. PubMed ID: 30535959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets.
    Feng Z; Liu Y; Kuang Y; Yang S; Li J; Ye L; Huang J; Pei Q; Huang Y; Yang G
    Drug Des Devel Ther; 2022; 16():3-12. PubMed ID: 35018094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.
    Hussaini A; Olszanski AJ; Stein CA; Bosch B; Nemeth P
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):479-486. PubMed ID: 28695267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; De Porre P; Vermeulen A; Poggesi I; Nandy P
    Clin Pharmacokinet; 2017 Jan; 56(1):55-63. PubMed ID: 27324190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
    Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
    Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
    Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.